medicines patent pool

UPDATE ON PROGRESS OF MPP SUBLICENSEES

TILL JUNE 2025

SUMMARY

- This presentation showcases the progress made by MPP licensees (generic pharmaceutical companies).
- To date, MPP has signed agreements with 22 patent holders for 13 HIV antiretrovirals, 1 HIV technology platform, 3 hepatitis C direct-acting antivirals, 1 tuberculosis treatment, 4 long-acting technologies, 1 cancer treatment, 3 oral antiviral treatments for COVID-19, 1 post partum haemorrhage medicine and 16 Covid-19 technologies.
- Licensed products are developed by multiple MPP licensees, with an aim of encouraging competition, reducing market prices and providing faster access to medicines for people living in low- and middle-income countries (LMICs).
- Generic medicines are developed and filed with stringent regulatory authorities such as the U.S. Food and Drug Administration (USFDA) and the World Health Organization prequalification (WHO-PQ), ensuring availability of quality assured products in LMICs.
- This presentation gives a snapshot of the development of each licensed product and when the product may be filed with regulators. It also shows which countries the local filing is taking place in and when – thereby providing a clearer picture of availability of new formulations in each country.

PARTNERSHIPS WITH INNOVATORS ACROSS DIFFERENT DISEASE AREAS

TUBERCULOSIS

- Johns Hopkins University
- Pfizer

sutezolid

HIV

- abbvie — lopinavir, ritonavir
- Bristol Myers Squibb — atazanavir
- MSD — raltegravir (paediatric)
- ViiV Healthcare — abacavir (paediatrics); cabotegravir long-acting (for HIV PrEP and Treatment); dolutegravir
- Gilead — bictegravir; cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide; tenofovir disoproxil fumarate
- Boehringer Ingelheim — nevirapine (non-assert)
- Janssen — darunavir (paediatric; non-assert)
- NIH — darunavir related

CANCER

- Novartis — nilotinib

MATERNAL HEALTH

- Ferring Pharmaceuticals — heat-stable carbetocin

HEPATITIS C

- Bristol Myers Squibb — daclatasvir
- Pharco Pharmaceuticals — ravidasvir
- abbvie — glecaprevir/pibrentasvir

COVID-19

- CSIC — Elisa antibody Tech MVA-S(3P) (vaccine candidate)
- MSD — molnupiravir
- Pfizer — nirmatrelvir
- MVC Medigen Vaccine Biologics Corp — vaccine MVC-COV1901
- Universidad de Chile — NAb detection tech for SARS-COV-2
- NIH — Early stage vaccine & diagnostic tools
- Shionogi — ensitrelvir fumaric acid
- SD Biosensor — rapid diagnostic testing tech

LONG-ACTING TECHNOLOGIES

- University of Liverpool — solid drug nanoparticles technology (disease agnostic)
- MedinCell — mdc-STM (malaria LAI)
- Tandem Nano Ltd — LA tech for HCV, TB & malaria
- University of Washington — TLD LAI (HIV)

MPP PARTNERSHIPS WITH GENERICS AND PRODUCT DEVELOPERS

Hepatitis C

daclatasavir
Beximco
Cipla
Hetero
Laurus Labs
Natco
Zydus
Viatris

glecaprevir/pibrentasvir
Arene
Remington
USV
Viatris

HIV

abacavir (paed)
Aurobindo

atazanavir
Aurobindo
Cipla
Desano
Emcure
Viatris

bictegravir
Adcock Ingram
Arene
Aurobindo
Desano
Emcure
Laurus Labs
Lupin
Macleods

cabotegravir
Aurobindo
Cipla
Viatris

cobicistat
Adcock Ingram
Arene
Emcure
Lupin

dolutegravir
Adcock Ingram#
Celltrion#
Cipla#
Desano#
Emcure#
Hetero^
Laurus Labs#
Lupin#
Macleods#
Mangalam
Micro Labs#
Strides#
Sun Pharma^
Viatris^

elvitegravir
Adcock Ingram
Arene

emtricitabine
Adcock Ingram
Arene
Emcure
Lupin

Lopinavir, ritonavir
Adcock Ingram
Arene
Aurobindo
Cipla*
Desano
Emcure
Hetero**
Lupin
Sun Pharma

raltegravir / Paed
Lupin

tenofovir alafenamide
Adcock Ingram
Aurobindo
Desano
Emcure
Laurus Labs
Lupin
Macleods
Micro Labs
Natco

tenofovir disoproxil fumarate
Adcock Ingram
Arene

rapid diagnostic testing technology
Codix Bio!

elisa antibody technology
Biotech Africa!

COVID-19 & Technology

nirmatrelvir
Apeloa
Arene
Celltrion
Cipla
Desano
Dongbang
Dr. Reddy's
Fosun Pharma
Hetero
Huahai
Jiuzhou
Magnachem
Neolpharma
SMS Pharma
Strides
Torrent
Viatris

molnupiravir
Biophore
Desano
Fosun
Kimia Farma
MSN
SMS Pharma

Tuberculosis

ensitrelvir
Charioteer
Fosun
Hetero
Laurus Labs
Lekhim
Lepu
Stellapharm

Cancer

sutezolid / John Hopkins University
TB Alliance!

sutezolid / Pfizer
Gates Medical Research Insititute!

nilotinib
Dr. Reddy's
Eugia
Hetero
PT Anvita Pharma

* Only LPV/r paed licence **Also have LPV/r paed licence # Also have DTG paed licence ^Also have DTG paed & UMICs licence !product developer

TRIANGLE CHARTS

Triangle charts represent a comparative analysis of each MPP licensee’s filings with WHO-PQ and/or USFDA for each product

TRIANGLE CHARTS: A SNAPSHOT



Companies approved Companies filed Companies planning to file

Note: *Each triangle represents a manufacturer and timelines represent date of filing*

See following slides for explanation

TRIANGLE CHARTS EXPLAINED (1/7)



TRIANGLE CHARTS EXPLAINED (2/7)



TRIANGLE CHARTS EXPLAINED (3/7)



No. of companies that have **received approval out of total companies filed** with WHO-PQ/USFDA

TRIANGLE CHARTS EXPLAINED (4/7)



Total no. of **companies** that **have been approved by** WHO-PQ/USFDA

TRIANGLE CHARTS EXPLAINED (5/7)

Outlined triangles (▽) represent companies **developing the product** and **planning to file** with WHO-PQ and/or USFDA



▽ Companies planning to file

Note: *Each triangle represents a manufacturer and timelines represent date of filing*

TRIANGLE CHARTS EXPLAINED (6/7)



▼ Companies filed

Note: *Each triangle represents a manufacturer and timelines represent date of filing*

TRIANGLE CHARTS EXPLAINED (7/7)

Circled triangles ▼ represent companies who have **completed the product development** and have **received approvals** from WHO-PQ and/or USFDA



▼ **Companies approved**

Note: *Each triangle represents a manufacturer and timelines represent date of filing*

medicines
patent
pool

ADULT HIV

MEDICINESPATENTPOOL.ORG

CURRENT SUBLICENSEES

FOR VIIV-MPP DOLUTEGRAVIR LICENCE

14 Dolutegravir Sub-licensee Agreements

adcock ingram

Cipla

CELLTRION

DESANO

Emcure cure and beyond

HETERO

LAURUS Labs Knowledge . Innovation . Excellence

LUPIN

MACLEODS

MANGALAM

MICRO LABS LIMITED

Mylan

Strides

SUN PHARMA

*Aurobindo is a direct licensee of ViiV. A tripartite agreement Aurobindo-ViiV-MPP has been signed. For the purposes of this presentation only, data from Aurobindo will be included in the presentation.

Note: the following presentation contains updates as of June 2025, however approvals through September 2025 are included.

DTG 50MG: Filing Timelines



Companies approved Companies filed

Note: *Each triangle represents a manufacturer and timelines represent date of filing*

12 MPP LICENSEES HAVE DEVELOPED DTG 50MG, OF WHICH 11 ARE READY TO COMMERCIALIZE THE PRODUCT

Licensees Approved*: Aurobindo, Cipla, Desano, Emcure, Hetero, Laurus, Macleods, Micro Labs, Mylan, Strides, Sun Pharma

1 licensee awaiting WHO-PQ approval

*USFDA and/or WHO-PQ

Data as of June 2025

DTG 50MG: COUNTRY WISE FILING STATUS

Generic DTG 50mg has been filed in 81 countries, which contribute to an effective coverage of 93.8% PLHIV^

APPROVED (68)
90.3% PLHIV^

Anguilla*	**Botswana**	**Costa Rica***	**Honduras**	**Malaysia**	**Niger**	**Saint Vincent and the Grenadines***	**Ukraine**
Antigua and Barbuda*	**Burkina Faso**	**Côte d'Ivoire**	**India**	**Mauritius**	**Nigeria**	**Senegal**	**Uruguay***
Armenia	**Burundi**	**Dominica***	**Indonesia**	**Moldova**	**Oman***	**South Africa**	**Uzbekistan**
Azerbaijan	**Cambodia**	**Dominican Republic***	**Iran***	**Montserrat***	**Pakistan**	**Tajikistan**	**Zambia**
Bahamas*	**Cameroon**	**Ecuador**	**Kazakhstan**	**Morocco**	**Panama***	**Tanzania**	**Zimbabwe**
Barbados*	**Chad**	**Ethiopia**	**Kenya**	**Mozambique**	**Peru***	**Thailand***	
Belarus	**Chile***	**Ghana**	**Kyrgyzstan**	**Myanmar**	**Philippines**	**Turkmenistan**	
Benin	**Congo**	**Grenada**	**Madagascar**	**Namibia**	**Rwanda**	**Turks and Caicos Islands***	
Bhutan	**Congo, DR**	**Guatemala**	**Malawi**	**Nicaragua**	**Saint Lucia***	**Uganda**	

FILED (13)
3.5% PLHIV^

Algeria	Colombia	**Jamaica**	**Viet Nam**
Angola	**El Salvador**	**Mali**	
Bahrain	**Gabon**	**Paraguay***	
Bolivia	**Gambia**	**Sri Lanka**	

- New filings and approvals in green *vis-à-vis last update (Q4-24)*
- Countries where DTG 50mg has been sold indicated in **bold type**

* Countries not included in DTG Adult licence but supply by MPP licensees permitted if no patent is being infringed in that country

^ People living with HIV (2024) in the licensed territory (refer MPP-ViiV DTG licence agreement and MPP-ViiV DTG UMIC licence) and countries with no patent infringements

Note: Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions

Data as of June 2025

DTG 50MG IMPACT MAP

Generic DTG 50mg sales have occurred in 128 countries in which 99.2% of PLHIV^ reside



FILED IN **13** COUNTRIES

APPROVED IN **68** COUNTRIES

SUPPLIED IN **128** COUNTRIES

Note: Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions
^ People living with HIV (2024) in the licensed territory and countries with no patent infringements
#For licensed territory, refer:
MPP-ViiV DTG adult licence
MPP-ViiV DTG UMIC licence

Data as of June 2025

TDF/3TC/DTG (TLD): Filing Timelines



13 MPP LICENSEES HAVE DEVELOPED TDF/3TC/DTG AND ALL ARE READY TO COMMERCIALIZE THE PRODUCT

Licensees Approved*: Aurobindo, Celltrion, Cipla, Desano, Emcure, Hetero, Laurus, Lupin, Macleods, Micro Labs, Mylan, Strides, Sun Pharma

1 licensee awaiting USFDA approval

*USFDA and/or WHO-PQ

Data as of June 2025

TDF/3TC/DTG (TLD): COUNTRY WISE FILING STATUS

TDF/3TC/DTG has been filed in 87 countries which contribute to an effective coverage of 94.8% PLHIV^

APPROVED (74)
90.7% PLHIV^

Anguilla*	**Bhutan**	**Congo, DR**	**Guatemala**	**Kyrgyzstan**	**Montserrat***	**Philippines**	**Tanzania**	**Zambia**
Antigua and Barbuda*	**Botswana**	**Côte d'Ivoire**	**Guyana**	**Madagascar**	**Mozambique**	**Rwanda**	**Thailand**	**Zimbabwe**
Armenia	**Burkina Faso**	**Dominica***	**Haiti**	**Malawi**	**Myanmar**	**Saint Kitts and Nevis***	**Turkmenistan**	
Azerbaijan	**Burundi**	**Eritrea**	**Honduras**	**Malaysia**	**Namibia**	**Saint Lucia***	**Turks and Caicos Islands***	
Bahamas*	**Cambodia**	**Ethiopia**	**India**	**Mali**	**Nepal**	**Saint Vincent and the Grenadines***	**Uganda**	
Barbados*	**Cameroon**	**Gabon**	**Indonesia**	**Mauritania**	**Niger**	**Senegal**	**Ukraine**	
Belarus	**Chad**	**Gambia**	**Jamaica**	Mauritius	**Nigeria**	**South Africa**	Uruguay*	
Belize*	**Chile***	**Ghana**	**Kazakhstan**	**Moldova**	**Panama***	**Suriname***	**Uzbekistan**	
Benin	**Congo**	**Grenada***	**Kenya**	**Morocco**	**Peru***	**Tajikistan**	**Viet Nam**	

FILED (13)
4% PLHIV^

Angola	**Guinea**	**Sierra Leone**	**Togo**
Bolivia	**Guinea Bissau**	**South Sudan**	
Costa Rica*	**Lebanon**	**Sri Lanka**	
Ecuador	**Pakistan**	**Sudan**	

New filings and approvals in green *vis-à-vis last update (Q4-24)*
Countries where TLD has been sold indicated in **bold type**
* Countries not included in DTG Adult licence but supply by MPP licensees permitted if no patent is being infringed in that country
^ People living with HIV (2024) in the licensed territory (refer MPP-ViiV DTG licence agreement and MPP-ViiV DTG UMIC licence) and countries with no patent infringements and with compulsory licence issued
Note: Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions

Data as of June 2025

TLD IMPACT MAP

Generic TLD sales have occurred in 119 countries in which 99.6% of PLHIV^ reside



FILED IN **13** COUNTRIES

APPROVED IN **74** COUNTRIES

SUPPLIED IN **119** COUNTRIES

Note: Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions
^ People living with HIV (2024) in the licensed territory and countries with no patent infringements
#For licensed territory, refer:
MPP-ViiV DTG adult licence
MPP-ViiV DTG UMIC licence

Data as of June 2025

COUNTRIES OF SALE OF DTG BASED TREATMENTS (ADULT) (2017 to JUNE 2025)

COUNTRIES OF SALE (129)					
Afghanistan	Cabo Verde	Ethiopia	Lao PDR	Nigeria	Suriname
Albania	Cambodia	Fiji	Lebanon	**Oman**	**Syrian Arab Republic**
Algeria	Cameroon	Gabon	Lesotho	Pakistan	Tajikistan
Angola	Central African Republic	Gambia (the)	Liberia	Panama	Tanzania, United Republic of
Anguilla	Chad	Georgia	Libya	Papua New Guinea	Thailand
Antigua and Barbuda	Chile	Ghana	Madagascar	Paraguay	Timor-Leste
Argentina	**Colombia**	Grenada	Malawi	Peru	Togo
Armenia	**Comoros**	Guatemala	Malaysia	Philippines	Tunisia
Azerbaijan	Congo	Guinea	Mali	Rwanda	Turkmenistan
Bahamas	Congo, DR	Guinea-Bissau	Mauritania	Saint Kitts and Nevis	Turk and Caicos
Bangladesh	Costa Rica	Guyana	**Mauritius**	Saint Lucia	Uganda
Barbados	Côte d'Ivoire	Haiti	Micronesia	Saint Vincent and the Grenadines	Ukraine
Belarus	Cuba	Honduras	Moldova, Republic of	Sao Tome and Principe	**Uruguay**
Belize	Djibouti	India	Mongolia	Senegal	Uzbekistan
Benin	Dominica	Indonesia	**Montserrat**	Seychelles	Venezuela
Bermuda	Dominican Republic	Iran (Islamic Republic of)	Morocco	Sierra Leone	Vietnam
Bhutan	Ecuador	Jamaica	Mozambique	Somalia	Yemen
Bolivia	**Egypt**	**Jordan**	Myanmar	South Africa	Zambia
Botswana	El Salvador	Kazakhstan	Namibia	South Sudan	Zimbabwe
British Virgin Island	Equatorial Guinea	Kenya	Nepal	Sri Lanka	-
Burkina Faso	Eritrea	Kosovo	Nicaragua	State of Palestine	-
Burundi	Eswatini	Kyrgyzstan	Niger	Sudan	-

Analysis includes sales DTG 50mg, TLD, ALD Adult, TAF-ED, TAF-LD, DTG/3TC, DTG/RPV

Sale of only TLD

Sale of only DTG 50mg

Data as of June 2025

CUMULATIVE PACKS SOLD: DTG 50MG (2017 to June 2025)

72 million packs of DTG 50mg sold till June 2025



Source: confidential sales data by MPP licensees

DTG 50mg Total Packs

Data as of June 2025

CUMULATIVE PACKS SOLD: TLD (2018 to June 2025)

1.44 Billion packs of TLD sold till June 2025



Source: confidential sales data by MPP licensees

DTG 50mg Total Packs

Note: Packs of 28's, 90's & 180's converted to 30's for this analysis

Data as of June 2025

TOP COUNTRY RECIPIENTS OF ADULT DTG BASED FORMULATIONS (2017 to June 2025)

Top 20 countries receiving Adult DTG based treatments



Source: confidential sales data by MPP licensees

Note: Packs of 28's, 90's & 180's converted to 30's for this analysis

Analysis includes sales DTG 50mg, TLD, ALD Adult, TAF-ED, TAF-LD, DTG/3TC, DTG/RPV

Data as of June 2025

ABC/3TC/DTG ADULT (ALD): Filing Timelines



Companies approved Companies filed

Note: *Each triangle represents a manufacturer and timelines represent date of filing*

6 MPP LICENSEES HAVE DEVELOPED ABC/3TC/DTG ADULT FORMULATION, OF WHICH: 5 ARE READY TO COMMERCIALIZE

Licensees Approved: Aurobindo, Cipla, Emcure, Hetero, Laurus

1 licensee awaiting USFDA approval | 1 licensee awaiting WHO-PQ approval

Data as of June 2025

ABC/3TC/DTG (ALD): COUNTRY WISE FILING STATUS

ABC/3TC/DTG has been filed in 40 countries which contribute to an effective coverage of 89% PLHIV^

APPROVED (23)
73.5% PLHIV^

Botswana	**Gabon**	**Kenya**	**Namibia**	Tanzania	Uzbekistan
Cambodia	Ghana	**Kyrgyzstan**	Nigeria	**Uganda**	Zambia
Cameroon	**India**	Malawi	Rwanda	**Ukraine**	**Zimbabwe**
Ethiopia	**Kazakhstan**	Myanmar	**South Africa**	**Uruguay***	

FILED (17)
15.6% PLHIV^

Azerbaijan	**Côte d'Ivoire**	Moldova	Senegal	Viet Nam
Belarus	Guatemala	Mozambique	Sri Lanka	
Benin	Indonesia	Pakistan	Tajikistan	
Congo, DR	Jamaica	Philippines	Thailand	

New filings and approvals in green *vis-à-vis last update (Q4-24)*
Countries where ALD has been sold indicated in **bold type**

- Countries not included in DTG Adult licence but supply by MPP licensees permitted if no patent is being infringed in that country

^ People living with HIV (2024) in the licensed territory (refer MPP-ViiV DTG licence agreement and MPP-ViiV DTG UMIC licence) and countries with no patent infringements

Note: Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions

Data as of June 2025

ALD ADULT IMPACT MAP

Generic ALD Adult sales have occurred in 27 countries in which 52.3% of PLHIV^ reside



FILED IN **17** COUNTRIES

APPROVED IN **23** COUNTRIES

SUPPLIED IN **27** COUNTRIES

Note: Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions
^ People living with HIV (2024) in the licensed territory and countries with no patent infringements
#For licensed territory, refer:
MPP-ViiV DTG adult licence
MPP-ViiV DTG UMIC licence

Data as of June 2025

DTG/3TC: Filing Timelines



Companies approved | Companies filed | Companies planning to file

Note: *Each triangle represents a manufacturer and timelines represent date of filing*

4 MPP LICENSEES HAVE DEVELOPED DTG/3TC FORMULATION, OF WHICH: 3 ARE READY TO COMMERCIALIZE

Licensee Approved: Cipla, Emcure, Hetero

1 licensee awaiting USFDA approval | 2 additional licensee developing

Data as of June 2025

DTG/RPV: Filing Timelines



Companies approved | Companies filed | Companies planning to file

Note: *Each triangle represents a manufacturer and timelines represent date of filing*

2 MPP LICENSEES HAVE DEVELOPED DTG/RPV FORMULATION, OF WHICH: 1 IS READY TO COMMERCIALIZE

Licensee Approved: Lupin

1 licensee awaiting USFDA approval | 2 additional licensee developing

Data as of June 2025

CURRENT SUBLICENSEES

FOR VIIV-MPP DOLUTEGRAVIR LICENCE

AND

GILEAD-MPP TENOFOVIR ALAFENAMIDE LICENCE

7 with both Dolutegravir and Tenofovir Alafenamide Sub-licensee Agreements

adcock ingram

DESANO

Emcure cure and beyond

LAURUS Labs Chemistry for Better Living

LUPIN

MACLEODS

MICRO LABS LIMITED

5 Dolutegravir Sub-licensee Agreements

Cipla

HETERO

Mylan

Strides

SUN PHARMA

1 Tenofovir Alafenamide Sub-licensee Agreements

AUROBINDO

*Aurobindo is a direct licensee of ViiV. A tripartite agreement Aurobindo-ViiV-MPP has been signed. For the purposes of this presentation only, data from Aurobindo will be included in the presentation.
Cipla, Hetero, Strides, Sun Pharma and Mylan are direct licensees of Gilead. For the purposes of this presentation only, data from them will be included in the presentation.

Note: the following presentation contains updates as of June 2025, however approvals through September 2025 are included.

TAF/FTC/DTG (TAF-ED): Filing Timelines



Companies approved | Companies filed | Companies planning to file

Note: *Each triangle represents a manufacturer and timelines represent date of filing*

9 MPP LICENSEES HAVE DEVELOPED TAF/FTC/DTG FORMULATION, OF WHICH: 6 ARE READY TO COMMERCIALIZE

Licensees Approved: Aurobindo, Cipla, Hetero, Laurus, Lupin, Viatris

1 licensee awaiting USFDA approval | 4 licensees awaiting WHO-PQ approval | 1 additional licensee developing

Data as of June 2025

TAF/FTC/DTG (TAF-ED): COUNTRY WISE FILING STATUS

TAF/FTC/DTG has been filed in 50 countries which contribute to an effective coverage of 94% of PLHIV^

APPROVED (30) 85.8% PLHIV^				
Belarus	Congo, DR	**India**	**Myanmar**	**Tanzania**
Botswana	**Dominican Republic**	Kazakhstan	**Namibia**	**Thailand**
Burkina Faso	Ethiopia	**Kenya**	**Nigeria**	**Uganda**
Cambodia	Gabon	Kyrgyzstan	**Philippines**	**Ukraine**
Cameroon	Ghana	Malawi	Rwanda	**Zambia**
Congo	**Guatemala**	Mozambique	**South Africa**	**Zimbabwe**

FILED (20) 8.2% PLHIV^				
Angola	Côte d'Ivoire	Indonesia	**Moldova**	**Senegal**
Benin	Eritrea	Jamaica	Morocco	**Sri Lanka**
Bolivia	Gambia	Madagascar	Niger	Tajikistan
Burundi	Guinea	**Mali**	Pakistan	**Viet Nam**

New filings and approvals in green *vis-à-vis last update (Q4-24)*
Countries where TAF-ED has been sold indicated in **bold type**
^ People living with HIV (2024) in the licensed territory (refer MPP-Gilead TAF licence agreement)
Note: Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions

Data as of June 2025

TAF/FTC/DTG IMPACT MAP

TAF-ED sales have occurred in 30 countries in which 63.3% of PLHIV^ reside



FILED IN **20** COUNTRIES

APPROVED IN **30** COUNTRIES

SUPPLIED IN **30** COUNTRIES

Note: Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions

^ People living with HIV (2023) in the licensed territory (refer MPP-Gilead TAF licence agreement)

Data as of June 2025

TAF/3TC/DTG (TAF-LD): Filing Timelines



4 MPP LICENSEES HAVE DEVELOPED TAF/3TC/DTG FORMULATION, OF WHICH: 4 ARE READY TO COMMERCIALIZE

Licensees Approved: Cipla, Laurus, Lupin, Viatris

2 licensees awaiting WHO-PQ approval | 4 additional licensees developing

Data as of June 2025

TAF/3TC/DTG (TAF-LD): COUNTRY WISE FILING STATUS

TAF/3TC/DTG has been filed in 23 countries

APPROVED (18)				
Botswana	Congo, DR	Malawi	Rwanda	Zambia
Burkina Faso	Ethiopia	Mozambique	**South Africa**	**Zimbabwe**
Cameroon	India	**Namibia**	**Tanzania**	
Congo	**Kenya**	Nigeria	**Uganda**	

FILED (5)				
Benin	Côte d'Ivoire	Ghana	Senegal	Viet Nam

New filings and approvals in green *vis-à-vis last update (Q4-24)*
Countries where TAF-LD has been sold indicated in **bold type**
Note: Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions

Data as of June 2025

TAF/3TC/DTG IMPACT MAP

TAF-LD sales have occurred in 11 countries in which 45.9% of PLHIV^ reside



FILED IN **5** COUNTRIES

APPROVED IN **18** COUNTRIES

SUPPLIED IN **11** COUNTRIES

Note: Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions

^ People living with HIV (2023) in the licensed territory (refer MPP-Gilead TAF licence agreement)

Data as of June 2025

CURRENT SUBLICENSEES

FOR GILEAD-MPP TENOFOVIR ALAFENAMIDE LICENCE

9 Tenofovir Alafenamide Sub-licensee Agreements

adcock ingram

AUROBINDO

DESANO

Emcure cure and beyond

LAURUS Labs Chemistry for Better Living

LUPIN

MACLEODS

MICRO LABS LIMITED

NATCO

TAF/FTC: Filing Timelines



Companies approved | Companies filed | Companies planning to file

Note: *Each triangle represents a manufacturer and timelines represent date of filing*

6 MPP LICENSEES HAVE DEVELOPED TAF/FTC FORMULATION, OF WHICH: 4 ARE READY TO COMMERCIALIZE

Licensees Approved: Aurobindo, Laurus, Lupin, Macleods

2 licensees awaiting USFDA approval | 2 licensees awaiting WHO PQ approval

Data as of June 2025

medicines
patent
pool

PAEDIATRIC HIV

MEDICINESPATENTPOOL.ORG

DTG DT PAED (10MG SCORED): Filing Timelines



3 MPP LICENSEES HAVE DEVELOPED DTG DT PAED FORMULATION AND ALL ARE READY TO COMMERCIALIZE THE PRODUCT

Licensees Approved*: Macleods, Micro labs, Viatris

*USFDA and/or WHO-PQ

Data as of June 2025

DTG DT PAED (10MG SCORED): COUNTRY WISE FILING STATUS

Generic DTG DT 10mg has been filed in 41 countries which contribute to an effective coverage of 91% of CLHIV^

APPROVED (28) 83.8% PLHIV^					
Botswana	**Congo, DR**	**India**	**Mozambique**	**South Africa**	**Uzbekistan**
Burkina Faso	**Dominican Republic**	**Kenya**	**Myanmar**	**Tanzania**	**Zambia**
Cameroon	**Ethiopia**	**Madagascar**	**Namibia**	**Thailand**	**Zimbabwe**
Chad	**Ghana**	**Malawi**	**Nigeria**	**Togo**	
Congo	**Guatemala**	**Mali**	**Rwanda**	**Uganda**	

FILED (12) 7.2% PLHIV^		
Angola	**Côte d'Ivoire**	**Niger**
Benin	**Gabon**	**Philippines**
Bolivia	**Gambia**	**Senegal**
Burundi	**Indonesia**	**Viet Nam**

New filings and approvals in green *vis-à-vis last update (Q4-24)*
Countries where DTG DT 10MG has been sold indicated in **bold type**
^ Children living with HIV (2024) in the licensed territory (refer MPP-ViiV DTG Paed licence agreement) and countries with no patent infringements
Note: Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions

Data as of June 2025

DTG DT 10MG IMPACT MAP

Generic DTG DT 10mg sales have occurred in 103 countries in which 99.5% of CLHIV^ reside



FILED IN **12** COUNTRIES

APPROVED IN **28** COUNTRIES

SUPPLIED IN **103** COUNTRIES

Note: Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions

^ Children living with HIV (2024) in the licensed territory (refer MPP-ViiV DTG Paed licence agreement) and countries with no patent infringements

Data as of June 2025

ABC/3TC/DTG (ALD) PAED: Filing Timelines



7 MPP LICENSEES HAVE DEVELOPED ABC/3TC/DTG (ALD) PAED FORMULATION, OF WHICH: 5 ARE READY TO COMMERCIALIZE

Licensees Approved*: Aurobindo, Cipla, Lupin, Macleods, Viatris

3 licensees awaiting USFDA approval | 1 licensee awaiting WHO PQ approval

*USFDA and/or WHO-PQ

Data as of June 2025

ABC/3TC/DTG PAED : COUNTRY WISE FILING STATUS

Generic ALD paed has been filed in 33 countries, of which approval have been received in 18 countries

APPROVED (18)				
Botswana	**Congo DR**	India	**Rwanda**	**Zambia**
Burkina Faso	**Ethiopia**	**Kenya**	South Africa	**Zimbabwe**
Cameroon	Gabon	**Malawi**	Tanzania	
Chad	Ghana	**Mozambique**	**Uganda**	

FILED (15)				
Angola	**Burundi**	Eritrea	**Mali**	**Niger**
Belarus	Congo	Gambia	**Myanmar**	**Nigeria**
Benin	**Côte d'Ivoire**	Madagascar	**Namibia**	Senegal

New filings and approvals in green *vis-à-vis last update (Q4-24)*
Country where ALD paed has been sold indicated in **bold type**
Note: Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions

Data as of June 2025

ABC/3TC/DTG PAED IMPACT MAP

Generic ALD Paed sales have occurred in 34 countries in which 66.6% of CLHIV^ reside



FILED IN **15** COUNTRIES

APPROVED IN **18** COUNTRIES

SUPPLIED IN **34** COUNTRIES

Note: Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions

^ Children living with HIV (2024) in the licensed territory (refer MPP-ViiV DTG Paed licence agreement) and countries with no patent infringements

Data as of June 2025

COUNTRIES OF SALE OF DTG BASED TREATMENTS (PAEDIATRIC) (2021 to JUNE 2025)

COUNTRIES OF SALE (103)					
Albania	**Comoros**	Guinea	Malaysia	Senegal	**Yemen**
Angola	Congo	Guinea-Bissau	**Mali**	Sierra Leone	**Zambia**
Argentina	**Congo DR**	Guyana	Mauritania	**Somalia**	**Zimbabwe**
Armenia	**Côte d'Ivoire**	**Haiti**	Mauritius	South Africa	-
Azerbaijan	Cuba	Honduras	Moldova, Republic of	**South Sudan**	-
Bangladesh	Djibouti	India	Morocco	Sri Lanka	-
Belarus	Dominican Republic	Indonesia	**Mozambique**	Sudan	-
Belize	Ecuador	Iran (Islamic Republic of)	**Myanmar**	Suriname	-
Benin	Egypt	Jamaica	**Namibia**	Syrian Arab Republic	-
Bhutan	El Salvador	Jordan	Nepal	Tajikistan	-
Bolivia	Equatorial Guinea	**Kenya**	**Nicaragua**	Tanzania, United Republic of	-
Botswana	Eritrea	Kosovo	**Niger**	Thailand	-
Burkina Faso	Eswatini	Kyrgyzstan	**Nigeria**	Timor-Leste	-
Burundi	**Ethiopia**	**Lao PDR**	Pakistan	**Togo**	-
Cabo Verde	Fiji	Lebanon	Panama	Tunisia	-
Cambodia	Gabon	Lesotho	**Papua New Guinea**	**Uganda**	-
Cameroon	Gambia	**Liberia**	Paraguay	Ukraine	-
Central African Republic	Georgia	Libya	**Philippines**	Uzbekistan	-
Chad	Ghana	Madagascar	**Rwanda**	Venezuela	-
Chile	Guatemala	**Malawi**	Sao Tome and Principe	Vietnam	-

Analysis includes sales DTG DT 10mg and ALD paed

Sale of both DTG DT and ALD paed

Sale of only DTG DT 10mg

Data as of June 2025

TOP COUNTRY RECIPIENTS OF PAEDIATRIC DTG BASED FORMULATIONS (2017 to June 2025)

Top 20 countries receiving Paediatric DTG based treatments



Source: confidential sales data by MPP licensees

Packs of 30's, 90's & 180's converted to 90's for this analysis

Analysis includes sales DTG DT 10mg and ALD Paediatric

Data as of June 2025

CABOTEGRAVIR

MEDICINESPATENTPOOL.ORG

CURRENT SUBLICENSEES

FOR VIIV-MPP CABOTEGRAVIR LICENCE

3 CAB-LA Sub-licensee Agreements

AUROBINDO

Cipla

Mylan

UPDATED VOLUNTARY LICENCE FOR CAB-LA (PrEP & TREATMENT)

(Announced at IAS-2025 (Kigali, Rwanda-July-2025)

1

Field of use:

HIV PrEP & treatment
(with RPV-LA)

2

Territory:

Covers 133 countries (private & public markets)

3

Quality assurance:

Recognizes WHO Listed Authorities (in addition to SRAs and WHO PQ)

Aligned with the new WHO recommendations, the 3 previously selected manufacturers of generic CAB-LA (Aurobindo, Cipla, Viatris) will be able to produce & supply generic CAB-LA for broad access as both HIV PrEP & treatment (to be co-administered with RPV-LA).

- *The earliest timeline for regulatory filing is by the first half of 2027 based on the current estimation by MPP*
- *SRAs: Stringent regulatory authorities / WHO PQ: WHO Prequalification of Medicines*
- *Sources: https://www.medspal.org*
  https://medicinespatentpool.org/progress-achievements/access-to-medicines-tracker
  https://medicinespatentpool.org/licence-post/cabotegravir-long-acting-la-for-hiv-pre-exposure-prophylaxis-prep

Unitaid
SAVE LIVES FASTER

Generic CAB-LA for PrEP: Tentative development timeline

Tentative timeline as of June 2025



- These timelines are not specific to any generic company; these are averages of the timelines required for different activities as shared by MPP licensees.
- **The earliest possible timeline for filing has shifted from H2 2026 to H1 2027 based on the current estimation by MPP. The main reason for this shift is the delay in procurement and qualification of the Netzsch Mill and dossier batch preparedness, which accounts for the time gap between end of prototype development and beginning of dossier batches manufacturing.**
- Due to the uncertainty associated with product development, especially for such long-acting products, the timelines quoted here are tentative and can change during development of the product.

medicines patent pool

HEPATITIS

MEDICINESPATENTPOOL.ORG

CURRENT SUBLICENSEES

FOR BMS-MPP DACLATASVIR LICENCE

7 Daclatasvir Sub-licensee Agreements

BEXIMCO PHARMA here's to life

Cipla

HETERO

LAURUS Labs
Knowledge . Innovation . Excellence

Mylan

NATCO

zydus
Dedicated To Life

DAC 30MG and 60MG: Filing Timelines



4 MPP LICENSEES HAVE DEVELOPED DAC 30/60 MG FORMULATION AND ALL ARE READY TO COMMERCIALIZE THE PRODUCT

Licensees Approved: Hetero, Laurus, Viatris, Zydus

Data as of June 2025

DAC 30 & 60MG : COUNTRY WISE FILING STATUS

Generic DAC 30/60 mg has been filed in 50 countries which contribute to an effective coverage of 61.2% PLHCV^

APPROVED (41) 58.7% PLHCV^				
Azerbaijan	Congo, DR	**Kyrgyzstan**	**Philippines**	**Ukraine**
Belarus	Ethiopia	Liberia	**Rwanda**	**Uzbekistan**
Benin	Gabon	Malawi	Senegal	**Viet Nam**
Burkina Faso	Ghana	**Malaysia**	Suriname	Zambia
Burundi	Guyana	Mozambique	**Tajikistan**	**Zimbabwe**
Cambodia	**India**	**Myanmar**	**Tanzania**	
Cameroon	**Indonesia**	Nicaragua	Thailand	
Chad	**Kazakhstan**	**Nigeria**	**Turkmenistan**	
Congo	Kenya	**Pakistan**	Uganda	

FILED (9) 2.4% PLHCV^		
Bolivia	Mali	**Nepal**
Côte d'Ivoire	**Mongolia**	**Paraguay**
Haiti	Namibia	Togo

New filings and approvals in green *vis-à-vis last update (Q4-24)*
Countries where either DAC 30mg or DAC 60mg have been sold indicated in **bold type**
^ People living with Hepatitis C (2023) in the licensed territory (refer MPP-BMS DAC licence agreement) and countries with no patent enforcements
 # Note: Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions

Data as of June 2025

DAC 60MG IMPACT MAP

DAC 60MG sales have occurred in 38 countries in which 56.1% of PLHCV^ reside and where MPP licensees have supplied ~1.67 million treatments*



FILED IN **9** COUNTRIES

APPROVED IN **41** COUNTRIES

SUPPLIED IN **38** COUNTRIES

Note: Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions

^ People living with Hepatitis C (2023) in the licensed territory (refer MPP-BMS DAC licence agreement) and countries with no patent enforcements

**Note: 1 HCV treatment = 12 weeks therapy (3 packs)*

Data as of June 2025

DAC/SOF: Filing Timelines



1 MPP LICENSEE HAS DEVELOPED DAC/SOF FORMULATION AND IS READY TO COMMERCIALIZE THE PRODUCT

Licensees Approved: Viatris

Data as of June 2025

DAC/SOF: COUNTRY WISE FILING STATUS

DAC/SOF has been filed in 19 countries, out of which approval has been received in 17 countries

APPROVED (17)		
Belarus*	**Indonesia**	**Tanzania**
Cambodia	Kenya	**Turkmenistan**
Côte d'Ivoire	Malawi	**Uganda**
Ethiopia	**Myanmar**	Zambia
Ghana	**Nigeria**	Zimbabwe
India	**Suriname**	

Countries where DAC/SOF has been sold indicated in **bold type**
* Countries not included in DAC licence but supply by MPP licensees permitted if no patent is being infringed in that country
Note: Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions

Data as of June 2025

DAC/SOF IMPACT MAP

DAC/SOF sales have occurred in 29 countries in which 53.9% of PLHCV^ reside and where MPP licensees have supplied ~196K treatments*



FILED IN **2** COUNTRIES

APPROVED IN **17** COUNTRIES

SUPPLIED IN **29** COUNTRIES

Note: Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions

^ People living with Hepatitis C (2023) in the licensed territory (refer MPP-BMS DAC licence agreement) and countries with no patent enforcements

**Note: 1 HCV treatment = 12 weeks therapy (3 packs)*

Data as of June 2025

CURRENT SUBLICENSEES

FOR GILEAD-MPP TENOFOVIR ALAFENAMIDE LICENCE

9 Tenofovir Alafenamide Sub-licensee Agreements

adcock ingram

AUROBINDO

DESANO

Emcure cure and beyond

LAURUS Labs Chemistry for Better Living

LUPIN

MACLEODS

MICRO LABS LIMITED

NATCO

TAF 25MG: Filing Timelines

Companies approved Companies planning to file

Note: *Each triangle represents a manufacturer and timelines represent date of filing*

2 MPP LICENSEES HAVE DEVELOPED TAF 25MG FORMULATION AND BOTH ARE READY TO COMMERCIALIZE THE PRODUCT

Licensees Approved: Laurus, Lupin

1 additional licensee developing

Data as of June 2025

TAF 25MG : COUNTRY WISE FILING STATUS

Generic TAF 25mg has been filed in 24 countries, of which approval has been received in 15 countries

APPROVED (15)			
India	**Lao**	**Thailand**	**Uzbekistan**
Indonesia	**Myanmar**	**Turkmenistan**	**Viet Nam**
Kazakhstan	**Philippines**	Uganda	Zimbabwe
Kyrgyzstan	**Tanzania**	**Ukraine**	

FILED (9)		
Azerbaijan	Kenya	Mongolia
Cambodia	Malawi	Nigeria
Ethiopia	Malaysia	Zambia

New filings and approvals in green *vis-à-vis last update (Q4-24)*
Country where TAF 25 mg has been sold indicated in **bold type**
Note: Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions

Data as of June 2025


medicines
patent
pool
COVID-19
MEDICINESPATENTPOOL.ORG

CURRENT SUBLICENSEES

FOR MSD-MPP MOLNUPIRAVIR LICENCE

6 Molnupiravir Sub-licensee Agreements

Biophore

DESANO

FOSUN PHARMA

kimia farma

MSN
Research for Better Medicines

sms pharmaceuticals ltd

MOL 200MG: Filing Timelines



Companies approved ▼ Companies filed ▽ Companies planning to file

Note: *Each triangle represents a manufacturer and timelines represent date of filing*

3 MPP LICENSEES HAVE DEVELOPED MOL 200MG FORMULATION, OF WHICH: 2 ARE READY TO COMMERCIALIZE

Licensees Approved: Desano, Fosun

1 licensee awaiting WHO-PQ approval | 1 additional licensee developing

Data as of June 2025

CURRENT SUBLICENSEES

FOR PFIZER-MPP NIRMATRELVIR LICENCE

17 Nirmatrevir Sub-licensee Agreements

APELOA 普洛

Arene Lifesciences Limited

CELLTRION

Cipla

DESANO

DONGBANG FTL
DongBang Future Tech & Life Co., Ltd.

Dr.Reddy's

FOSUN PHARMA

HETERO

华海药业
HUAHAI PHARMACEUTICAL

JIUZHOU
Pharmaceutical

Magnachem
Salud y Vida

NEOLPHARMA

sms
pharmaceuticals ltd

Strides

torrent
PHARMA

Mylan

NIR + RTV (Co-pack) : Filing Timelines



9 MPP LICENSEES HAVE DEVELOPED NIR+RTV (CO-PACK) FORMULATION, OF WHICH: 7 ARE READY TO COMMERCIALIZE

Licensees Approved: Apeloa, Celltrion, Desano, Fosun, Hetero, Huahai, Viatris

2 licensees awaiting WHO-PQ approval

Data as of June 2025

COVID-19 PRODUCTS: COUNTRY WISE FILING STATUS

NIR300mg +RTV100mg (Co-pack) has been filed in 27 countries, of which approval has been received in 11 countries

APPROVED (11)		
Botswana	**Ghana**	Mali
Cambodia	India	South Africa
Congo DR	Laos	Tanzania
Ethiopia	**Malawi**	

FILED (9)			
Burkina Faso	Indonesia	Namibia	Uganda
El Salvador	Kenya	Nicaragua	Viet Nam
Gabon	Mongolia	Philippines	**Zambia**
Honduras	Morocco	**Senegal**	Zimbabwe

MOL 200mg has been filed in 7 countries, of which approval has been received in 5 countries

APPROVED (11)		
India	Pakistan	Viet Nam
Indonesia	Philippines	

FILED (9)	
Ghana	Thailand

New filings and approvals in green *vis-à-vis last update (Q4-24)*
Country where Covid-19 products have been sold indicated in **bold type**
Note: Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions

Data as of June 2025

medicines
patent
pool

NILOTINIB

MEDICINESPATENTPOOL.ORG

CURRENT SUBLICENSEES

FOR NOVARTIS-MPP NILOTINIB LICENCE

4 Nilotinib Sub-licensee Agreements

BrightGene 博瑞医药

Dr.Reddy's

eugia

HETERO

NTB 150MG/200MG : Filing Timelines



3 MPP LICENSEES HAVE DEVELOPED NTB 150MG/200MG FORMULATION, OF WHICH: 2 ARE READY TO COMMERCIALIZE

Licensees Approved: Dr. Reddy's*, Hetero

1 licensee awaiting SRA approval | 1 additional licensee developing

* has approval for 50mg strength also

Data as of June 2025

NTB 150MG/200MG: COUNTRY WISE FILING STATUS

NTB 150mg/200mg has been filed in 18 countries, of which approval has been received in 7 countries

APPROVED (7)		
El Salvador	Guatemala	Honduras*
Indonesia	Nicaragua	**Philippines**
Sri Lanka**		

FILED (11)			
Botswana	Ethiopia	Ghana	Kenya
Morocco	Namibia	Tajikistan	Tanzania
Uganda	Zambia	Zimbabwe	

* Approval only for 200mg, ** approval only for 150mg
Country where NTB 150/200mg has been sold indicated in **bold type**
Note: Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions

Data as of June 2025





HEALTHY COMMUNITIES






AMBULANCE


THANK YOU